7Baggers

We provide you with 20 years of free, institutional-grade data for PSNL stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of PSNL. Explore the full financial landscape of PSNL stock.

Reported DateTickerType
2026-05-07PSNL10-QUrl
2026-02-26PSNL10-KUrl
2025-11-04PSNL10-QUrl
2025-08-05PSNL10-QUrl
2025-05-06PSNL10-QUrl
2025-02-27PSNL10-KUrl
2024-11-06PSNL10-QUrl
2024-08-07PSNL10-QUrl
2024-05-08PSNL10-QUrl
2024-02-28PSNL10-KUrl
2023-11-07PSNL10-QUrl
2023-08-08PSNL10-QUrl
2023-05-03PSNL10-QUrl
2023-02-23PSNL10-KUrl
2022-11-02PSNL10-QUrl
2022-08-03PSNL10-QUrl
2022-05-04PSNL10-QUrl
2022-02-24PSNL10-KUrl
2021-11-04PSNL10-QUrl
2021-08-04PSNL10-QUrl
2021-05-05PSNL10-QUrl
2021-02-25PSNL10-KUrl
2020-11-05PSNL10-QUrl
2020-08-06PSNL10-QUrl
2020-05-07PSNL10-QUrl
2020-03-25PSNL10-KUrl
2019-11-13PSNL10-QUrl
2019-08-13PSNL10-QUrl
2019-05-23PSNLS-1Url

Personalis, Inc
(NASDAQ:PSNL) 

PSNL stock logo

Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and dia...

Founded: 2011
IPO Price: $17 (Jun 20, 2019)
Full Time Employees: 181
CEO: John S. West  
Sector: Healthcare
Industry: Diagnostics & Research

Share this website to your friends
The information provided in this report about PSNL stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.